Procurement
Procurement
Procurement
Scientific advice and protocol assistance adopted during the CHMP meeting of 6-9 November 2023
CTIS newsflash – 10 November 2023
Clinical Trial Information System (CTIS) - Sponsor handbook
Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised
Nitrosamines EMEA-H-A5(3)-1490 - Questions and answers for marketing authorisation holders / applicants on the CHMP Opinion for the Article 5(3) of Regulation (EC) No 726/2004 referral on nitrosamine impurities in human medicinal products
Scientific recommendations on classification of advanced therapy medicinal products (January 2021 - September 2023)
Scientific recommendations on classification of advanced therapy medicinal products (January 2021 - October 2023)
Referral: Ocaliva, obeticholic acid, Article 20 procedures, Procedure started, 10/11/2023
Opinion/decision on a Paediatric investigation plan (PIP): Inclacumab, decision type: , therapeutic area: , PIP number: P/0545/2022